anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a phase 4 randomized open label prospective pilot study comparing the use of daptomycin versus vancomycin for peri-operative antibiotic prophylaxis in patients undergoing elective primary knee, hip or shoulder arthroplasty and are at risk for infection with methicillin resistant Staphylococcus aureus. The study population will include males and non-pregnant, non-lactating females 18 years of age or older, with history of methicillin-resistant Staphylococcus aureus infection or colonization, and undergoing primary elective hip, knee or shoulder arthroplasty. The target enrollment is 100 patients, who will be randomized to daptomycin or vancomycin in two 50 patient study groups. After signing the informed consent, patients will undergo pre-enrollment nasal screening for methicillin resistant Staphylococcus aureus to identify eligible patients. Patients with positive MRSA nasal screen will proceed with enrollment and get randomized into one of the two study groups. In one group, patients will receive one dose of daptomycin 6 mg/kg to be infused over 30 minutes. In this group, the infusion should be started and completed within 60 minutes of surgical incision. In the second group, patients will receive one dose of vancomycin 15 mg/kg to be infused over 1-2 hours of surgical incision according to the dose to avoid red man syndrome. In this group, the infusion should be started and completed within 120 minutes of surgical incision. After surgery, a second similar dose of vancomycin will be given 12 hours after the first dose to patients with creatinine clearance (CLcr.) of ≥50 ml/min. All patients in both groups will be asked to shower with chlorhexidine skin cleanser (HIBICLENS®) once daily from the neck down for 7days before surgery and apply Mupirocin ointment 2% to their nostrils twice daily for 5 days before surgery.

The patients will be evaluated on the day of surgery, at 2-3 days postoperatively, on discharge, at one month and three months follow up visits. During these study evaluations, patients will be assessed clinically for signs and symptoms of wound, and prosthetic joint infection (including pain, tenderness, swelling, erythema, poor wound healing and wound drainage) prior to hospital discharge, and at one, and three months follow up visits. Blood work including complete blood counts, erythrocytic sedimentation rate, c-reactive protein, and cultures will be ordered if clinical findings suggest infection. Bacterial isolates causing infections will be tested locally for antibiotic susceptibilities including daptomycin and vancomycin and saved for further testing if needed. Adverse effects and tolerability will be documented with the use of both drugs in the two patient groups. Data will be collected and analyzed with appropriate testing. The primary endpoint will be the success in prevention of postoperative SSI and prosthetic joint infection at one month postoperative follow up visit.
Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST 25 bilaterally, ST 29 bilaterally, SP 6 bilaterally, LR 3 bilaterally.
This is a multicenter, randomized , double-blind Phase II trial and the aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With Abiraterone and Docetaxel whether the patient's overall survival (OS) is superior to placebo. The Stage I part is a dose-escalation and -expansion study. Approximately 18\~24 patients in Stage I will receive fixed-dose of orally SHR3680 and only one of two dose levels of orally SHR3162. The Primary endpoints of the Stage I are incidence of adverse events(AE) and recommended phase 2 dose(RP2D). The Stage II part is a randomized , double-blind study. Approximately 90\~120 patients in Stage II will receive SHR3162 combined with SHR3680, in which one fixed-dose levels of SHR3162 will be selected based on the result of the Stage I.The Primary endpoint of the Stage II is overall survival(OS).
Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after surgery. After radiotherapy, patients will be actively monitored.
BACKGROUND: The perforator flap has garnered significant interest since its inception due to its advantage of not needing a vascular network at the deep fascial level. Perforator flaps are commonly utilized in different flap transplant surgeries, and the thigh flap is presently the most widely used perforator flap. Is it possible for the calf to replace the thigh as a more suitable site for harvesting materials? Currently, there is a lack of relevant anatomical research. This study aims to address this question from an anatomical and imaging perspective.
METHODS: This study used cadavers to observe the branches and courses of perforators on the calf and the distribution of skin branches using microdissection techniques, digital X-ray photography, and micro-computed tomography techniques.
RESULTS: The perforators had three main branches: the vertical cutaneous branch, the oblique cutaneous branch, and the superficial fascial branch. The superficial fascial branch traveled in the superficial fascia and connected with the nearby perforators. The vertical and oblique cutaneous branches entered the subdermal layer and connected with each other to create the subdermal vascular network.
CONCLUSIONS: We observed an intact calf cutaneous branch chain between the cutaneous nerve and the perforator of the infrapopliteal main artery at the superficial vein site. Utilizing this anatomical structure, the calfskin branch has the potential to serve as a substitute for thigh skin flap transplantation and may be applied to perforator flap transplantation in more locations.
This is a multicenter ,prospective, randomized double blind study. This study has a 2-arm design assessing the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent to the uncoated Bx VELOCITY™ stent, both mounted on Raptor® Stent Delivery Systems. A total of 100 patients will be entered in the study and will be randomized on a 1:1 basis. Patients who meet the eligibility criteria will be either randomized to Treatment A or Treatment B. Neither the investigator nor the patient will know which stent will be implanted. Patients will be followed at 30 days, 6, 9, and 12 months, and at 2, 3, 4 and 5 years post-procedure, with all patients undergoing repeat angiography at 8 months. Additionally, medical costs associated with the index hospitalization and length of stay, and repeat hospitalizations and costs associated with other relevant medical resource use during the 5 years follow-up period will be collected and analyzed.
BACKGROUND: Disuse is a typical phenotype of osteoporosis, but the underlying mechanism has yet to be identified in elderly patients. Disc collapse and intervertebral disc (IVD) fibrosis are two main pathological changes in IVD degeneration (IDD) progression, given that these changes affect load transmission patterns, which may lead to disuse osteoporosis of vertebral bodies and zygapophyseal joint (ZJ) osteoarthritis (ZJOA) biomechanically.
METHODS: Clinical data from 59 patients were collected retrospectively. Patient vertebral bony density, ZJOA grade, and disc collapse status were judged via CT. The IVD fibrosis grade was determined based on the FA measurements. Regression analyses identified potential independent risk factors for osteoporosis and ZJOA. L4-L5 numerical models with and without disc collapse and IVD fibrosis were constructed; stress distributions on the bony endplate (BEP) and zygapophyseal joint (ZJ) cartilages were computed in models with and without disc collapse and IVD fibrosis.
RESULTS: A significantly lower disc height ratio and significantly greater FA were recorded in patients with ZJOA. A significant correlation was observed between lower HU values and two parameters related to IDD progression. These factors were also proven to be independent risk factors for both osteoporosis and ZJOA. Correspondingly, compared to the intact model without IDD. Lower stress on vertebral bodies and greater stress on ZJOA can be simultaneously recorded in models of disc collapse and IVD fibrosis.
CONCLUSIONS: IVD fibrosis and disc collapse simultaneously aggravate vertebral body disuse osteoporosis and ZJOA by posteriorly shifting the load transmission pattern.
Patients receive lapatinib ditosylate PO QD and trastuzumab IV once weekly OR once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Participants weighing \<50 kg will receive 0.08 mg/kg of prucalopride oral solution (will draw the required volume from two bottles of 0.4 mg/mL to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive two 2 mg of prucalopride oral tablets, QD, for 36 weeks during the 40-week Part B Period. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
The invention relates to a silica gel scar treatment strip and its preparation method and belongs to the field of medical cosmetology. The silica gel scar treatment strip is composed of three layered structures including an upper layer, a middle layer and a lower layer. The upper layer is a ventilating polyurethane film or silica gel thin film layer; the middle layer is an autoadhesion silica gel layer; and the lower layer is a release protection film layer. Active substances and accessories are added in the autoadhesion silica gel layer. The ventilating polyurethane film or silica gel thin film is tiled on an operating console; the autoadhesion silica gel is uniformly mixed with the active substances and accessories to obtain a mixture; the mixture is uniformly smeared on the ventilating polyurethane film or silica gel thin film; a material obtained is heated to 50-70 DEG C for 15-35 min; the release protection film is pressed and coated and cut to a required specification; and packaging is carried out after passing inspection so as to obtain the product. The product of the invention has good air permeability, has strong skin fitness, is convenient to use and has remarkable effects of treating itching and aching feelings of scar parts and removing scars.
The invention belongs to the field of research of inflammatory bowel diseases, and particularly discloses application of omentum extract in preparation of a medicament for treating inflammatory bowel diseases. Application of omentum extract in preparing medicine for preventing and treating inflammatory bowel disease is provided. Application of omentum extract in preparing preparation for inhibiting colitis intestinal inflammatory factor secretion is provided. Application of omentum extract in preparing preparation for inhibiting colitis intestinal inflammatory factor secretion is provided. Application of intestinal inflammatory cytokines in preparing a preparation for inhibiting expression of reticulin. The omentum extract reduces the secretion of colitis intestinal inflammatory factors induced by Dextran Sodium Sulfate (DSS), and effectively improves intestinal inflammation; meanwhile, a corresponding scheme is provided for the adjustment of the reticulin.
Tuberculosis (TB) is a major global health problem. TB is the current leading cause of death due to an identifiable infectious agent worldwide. One of the highest priorities for tuberculosis control programs is to shorten anti-TB treatment while maintaining its effectiveness. Current 6-month short course chemotherapy regimens are over 95% effective for the treatment of tuberculosis when fully administered. Six months is a long time, however, and patients frequently discontinue anti-TB treatment once their symptoms have improved. The duration of standard short course chemotherapy is one of the major obstacles to its successful application and poses substantial challenges to programs with respect to patient adherence, program resource needs, and logistical requirements for directly observed therapy. The primary objective of this study is to assess the efficacy of shortening anti-TB treatment to 4 months in human immunodeficiency virus (HIV)-non-infected adults with drug-susceptible, non-cavitary pulmonary tuberculosis who convert their sputum culture to negative after 2 months of treatment. Secondary objectives of this study include: comparing pre-treatment sputum bacillary load in patients with and without cavitary disease; compare time after inoculation of BACTEC or Mycobacteria growth indicator tube (MGIT) liquid culture media until positive with semi-quantitative sputum acid fast bacteria (AFB) smear and culture on solid media as measures of pre-treatment sputum bacillary load; and determining the influence of immunologic characteristics of subjects pre-treatment, during treatment and at the end of therapy on rate of bacillary clearance and risk for relapse. A total of 758 HIV-non-infected adults, male or female, 18-60 years of age, with newly diagnosed initial episodes of sputum AFB smear-positive or -negative, culture-positive, non-cavitary, drug-susceptible pulmonary TB who are sputum culture negative after 2 months of anti-TB treatment will be randomly assigned to complete a total of 4 or 6 months of anti-TB therapy. The experimental regimen will include a total of 4 months of anti-TB treatment \[2 months of daily isoniazid (INH), rifampicin, pyrazinamide and ethambutol followed by 2 months of daily INH and rifampicin\]. The comparative regimen will include a total of 6 months standard short course anti-TB chemotherapy (2 months of daily INH, rifampicin, pyrazinamide and ethambutol followed by 4 months of daily INH and rifampicin). Subjects will be involved in study related procedures for approximately 30 months after beginning the initial anti-TB treatment.
The difference between venous and arterial carbon dioxide pressure (pCO2 gap), has been used as a diagnostic and prognostic tool. We aimed to assess whether perioperative pCO2 gaps can predict postoperative complications. This was a secondary analysis of a multicenter RCT comparing goal-directed therapy (GDT) to standard care in which 464 patients undergoing high-risk elective abdominal surgery were included. Arterial and central venous blood samples were simultaneously obtained at four time points: after induction, at the end of surgery, at PACU/ICU admission, and PACU/ICU discharge. Complications within the first 30 days after surgery were recorded. Similar pCO2 gaps were found in patients with and without complications, except for the pCO2 gap at the end of surgery, which was higher in patients with complications (6.0 mmHg [5.0-8.0] vs. 6.0 mmHg [4.1-7.5], p = 0.005). The area under receiver operating characteristics curves for predicting complications from pCO2 gaps at all time points were between 0.5 and 0.6. A weak correlation between ScvO2 and pCO2 gaps was found for all timepoints (ρ was between - 0.40 and - 0.29 for all timepoints, p < 0.001). The pCO2 gap did not differ between GDT and standard care at any of the selected time points. In our study, pCO2 gap was a poor predictor of major postoperative complications at all selected time points. Our research does not support the use of pCO2 gap as a prognostic tool after high-risk abdominal surgery. pCO2 gaps were comparable between GDT and standard care. Clinical trial registration Netherlands Trial Registry NTR3380.
Procedure for obtaining lipopeptides. Consists of the following stages: 1. "coupling" between the N-carbobenzo-lencina and the amina rental. By the method of mixed anhydride with isobutil-chloroformate in tetrahydrofuran medium. Once the derived carbobenzoxi is purified, it is hydrogenated catalytically in the presence of black paladio. 2. Reaction of l-phenylalanin with N-hydroxisuccinimidic ester of N-carbobenzoxi glycine in dioxane/oh. 3. The tripeptide is hydrogenated and reacted with N-hydroxisuccinimidic ester in dioxan/oh medium. 4. Hydrogenation of the tripeptide obtained and reaction with ester N-hydroxisuccinimidico in dioxanal medium with agitation at ambient temperature. 5. Hydrogenation of the derivatives of the first stage and reaction with the previous tetrapeptide, using diclohexil carbodiimide as a coupling agent. The lipopeptides obtained are hydrogened and purified in silica column eluing with chloroform methanol. (Machine-translation by Google Translate, not legally binding)
Perineural blocks with catheter placement are more and more frequently used. Few data dealing with infectious complications of perineural catheters exist. We assess incidence and localization of infectious complications of perineural catheters by means of computerized data acquisition. We prospectively evaluate perineural catheters placed at different sites for regional anesthesia and postoperative analgesia. The catheters were placed under standardized sterile conditions by using the nerve stimulator technique. Local inflammation is defined as the presence of at least two of the three signs: redness, pain on pressure or swelling. Infection is defined as the presence of at least two of the following criteria: pus at the catheter insertion site, fever, increased CRP and/or leukocytes requiring antibiotic therapy.
Iodine compensation is a unique and effective measure for preventing and treating iodine deficient diseases. Most of the existing iodine compensation measures are edible iodine compensation; an edible method for the iodine compensation is limited by edible quantity. Lipiodol injection is inconvenient. The existing toothpaste is only an oral hygiene article and does not have an iodine compensation function. The present invention introduces iodine compensation toothpaste which is composed of a toothpaste body and an iodine agent. The present invention has the double efficacy of cleaning teeth and oral hygiene and compensating iodine and is an iodine compensation measure with the advantages of simplicity, convenience, effectiveness, no side effect and convenient generalization and application.
Surface-active, non-leaching antimicrobial film forming compositions and methods for their application to preferably medical device surfaces are provided. The compositions form durable coatings with long-lasting antimicrobial efficacy without formation of a zone of inhibition. Optionally the films can be hydrophilic. Specific long-chain molecules of certain chemical reactivity are covalently bonded into a polymeric matrix. They maintain a long-term anti-microbial efficacy without being leached out into the aqueous environment. The polymeric matrix of the compositions contain functional groups, which covalently bond to an amine, thiol, carboxyl, aldehyde or hydroxyl active group of selected long chain quaternary ammonium compounds. Upon formation of a covalent bonding with the polymeric matrix the long chain compounds become immobilized but still maintain antimicrobial efficacy. They do not leach out over extended period of time into the aqueous environment and maintain an anti-microbial efficacy against microorganisms. The coating is useful to prevent bacterial colonization on a variety of surface including surfaces of medical devices.
The invention discloses a method of producing a medicine carrier from ficus carica polysaccharides and belongs to the field of medicine carriers. The method includes the steps of extracting ficus carica polysaccharides powder from ficus carica, performing hydrophobic modification to the structure of the ficus carica polysaccharides through ultrasonic wave modification, and performing hydrophilic modification to obtain amphipathic molecules, and finally swelling and freeze-drying the amphipathic molecules. The ficus carica polysaccharides is modified to prepare the amphipathic molecules, so that the medicine carrier is easy to prepare, has excellent bio-compatibility, low rejection reaction, good degradation performance and excellent thermal stability. The medicine carrier has high medicine carrying rate. Degraded products are low in toxic and side effects. The medicine has abundant raw material sources and low cost.
The breathing exercise group, which constitutes the placebo-control group, was first informed about correct breathing techniques by the researcher, and an informative training brochure prepared by the researcher, containing correct breathing exercise information, was given to them. The exercise was performed by the researcher and shown to the patient. The first exercise was performed by the patient under the supervision of the researcher. They were informed about the continuation of the breathing exercise program for 3 months, once a day for 10 minutes, starting from the 2nd exercise. Regular phone calls were made once a week.
Described embodiments include a system, method, and computer program product. A described system includes a receiver circuit that receives at least two medical images that each includes a respective region of interest of a mammalian body part. The receiver circuit also receives at least two reference images that each includes a respective landmark subsurface feature of the mammalian body part. Each landmark subsurface feature has a respective spatial relationship to a respective region of interest. The system includes a coordinate analysis circuit configured to determine a common frame of reference at least partially based on a landmark subsurface feature included in a reference image. The system includes a registration circuit configured to register the respective regions of interest. The registration is based on the determined common frame of reference. The system includes a computer-readable media configured to maintain informational data corresponding to the respective registered regions of interest.
Systems and methods provide visual presentation of clinical evidence to a user in association with a patient's anatomy. In certain examples, a patient information interface system to present an aggregated, graphical view of patient anatomy and history includes a data store to include images and patient history information and a processor to implement a user interface to accept user input. The processor provides a plurality of graphical representations of a human anatomy. Each graphical anatomy representation is to provide a view of a body system. Each graphical anatomy representation is to include one or more indicators corresponding to clinical events that have occurred in connection with a patient in the body system and are viewable through the graphical anatomy representation. Each of the one or more indicators is to be located at an anatomical location on the graphical representation affected by the clinical event corresponding to the indicator.
IMITREX (sumatriptan succinate) Injection is a selective 5-hydroxytryptamine1 receptor subtype agonist. Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1), and it has the following structure:

The empirical formula is C14H21N3O2S•C4H6O4, representing a molecular weight of 413.5.

Sumatriptan succinate is a white to off-white powder that is readily soluble in water and in saline.

IMITREX Injection is a clear, colorless to pale yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 0.5 mL of IMITREX Injection 8 mg/mL solution contains 4 mg of sumatriptan (base) as the succinate salt and 3.8 mg of sodium chloride, USP in Water for Injection, USP. Each 0.5 mL of IMITREX Injection 12 mg/mL solution contains 6 mg of sumatriptan (base) as the succinate salt and 3.5 mg of sodium chloride, USP in Water for Injection, USP. The pH range of both solutions is approximately 4.2 to 5.3. The osmolality of both injections is 291 mOsmol.